 In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods PMPs. For each PMP, dosing commenced 2 days before the anticipated onset of the menstrual migraine MM headache and continued for a total of 6 days. Patients were to take a loading dose of frovatriptan 5 mg two tablets twice daily on Day 1, followed by frovatriptan 2.5 mg twice daily on Days 2-6. During the study, patients were to visit the study site a total of 6 times. Efficacy andor safety assessments were performed at each visit. 